About the study

Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

1. Subjects with histologically/cytologically confirmed advanced malignancy (solid tumor) who must have exhausted all available standard therapy; or not a candidate for standard therapy.
2. Subject is able to provide written, informed consent before initiation of any study related procedures, and is able, in the opinion of the investigator, to comply with all the requirements of the study.
3. Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Key

Exclusion criteria

1. Prior treatment with a TIGIT inhibitor.
2. Symptomatic interstitial lung disease or inflammatory pneumonitis.
3. History of immune-related events that required immunotherapy treatment discontinuation.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.